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Abstract
Background: Bisphosphonate (BP)-related osteonecrosis of the jaw (BRONJ) disease is rare, but there are serious 
side-effects of BP therapy in patients. In some patients, surgery is needed and could not be cured. A standard test is not 
available showing the risk of jaw osteonecrosis in routine use. The measurement of serum C-terminal telopeptide (CTX) 
levels has been used in diseases of BRONJ resorption and antiresorptive therapy.
Aim: This paper is aimed at investigating the relationship between traumatic procedures and presence of BP-related 
osteonecrosis.
Materials and Methods: Thirty male Wistar albino rats with weighing 200 ± 20 g were used for the experimental procedures. 
Rats were randomly divided into three groups each containing 10 rats as follows: Group 1 (traumatic extraction group), 
Group 2 (atraumatic extraction group), and Group 3 (control group). All groups, zoledronic acid (ZA) (0.3 mg/kg/week)[1] 
was diluted with physiological saline and given subcutaneously for 2 months. After the 2 months, Group 1 was subjected to 
traumatic extraction of right first lower molars, and Group 2 was subjected to atraumatic extractions of the right first lower 
molars. Group 3 was subjected to no extractions as a control group. Animals were euthanized 32 days after tooth extractions, 
and the ZA administration protocol was maintained until the animals’ death. After sacrifice, blood samples were collected 
for C-terminal cross-linking telopeptide of type I collagen (CTX-1) levels, clinical and radiological findings were recorded.
Results: The bone resorption marker CTX-1 showed a significant difference among the groups. CTX-1 was measured 
significantly higher in blood samples of Group 2 (4.15 ± 0.34; P = 0.001) than Group 1 (3.77 ± 0.34; P = 0.0001). 
No, statistically significant changes were found between Groups 1 and 2 as for clinical and radiological assessment.
Conclusion: This study provides preliminary observations for the development of an animal model of BRONJ. Although 
clinical and radiological findings were not relevant, serum CTX values are reliable biochemical markers for predicting 
BRONJ and also atraumatic surgical procedures are important to prevent BRONJ.
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Introduction
Bisphosphonate (BP) is chemical analog of inorganic 
pyrophosphate. The BPs are widely used in the treatment 
of osteoporosis. BPs such as zoledronic acid (ZA) are 
used to treat bone disease in both multiple myeloma and 
breast cancer patients with bone metastasis.[2] BP‑related 
osteonecrosis of the jaw (BRONJ) is a well‑known adverse 
reaction of BPs including ZA.[3] BRONJ develops after oral 
trauma and is manifested by poor wound healing and soft 
tissue breakdown followed by necrosis of intra‑oral bone.[4] 
Oxidative stress induces DNA damage and ZA treatment 
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induces a DNA damage response in oral keratinocytes that 
activates the ubiquitin‑mediated proteolysis of cell cycle 
regulators, resulting in cell cycle arrest and repressive effects 
on cell viability, proliferation, and epithelial turnover.[5] 
The ubiquitin system is at the core of protein turnover as 
the main pathway for the degradation of proteins related 
to oxidative stress.[6] The BPs may induce the degenerative 
effects through decrease of antioxidant, antioxidant trace 
element and increase of lipid peroxidation in oral epithelium.
The most widely used serologic biochemical marker 
for stratifying the risk of BRONJ among BP users is the 
C‑terminal cross‑linking telopeptide of type I collagen 
(CTX‑1).[7] In situations of increased bone turnover, 
type I collagen is degraded by osteoclasts, which releases 
C‑terminal telopeptide (CTX) molecules. Collagen I is one 
of the most abundant constituents of bone, reaching up to 
90‑98% of the organic matrix.[8] It has been demonstrated 
that declines in serum levels of CTX can be quantified 
within weeks of initiation of BP therapy.[9]
This paper is aimed at investigating the relationship 




Thirty male Wistar albino rats weighing 200 ± 20 g were 
used for the experimental procedures. Animals were housed 
in individual cages with bedding. Standard rat food and 
tap water were available ad libitum for the duration of the 
experiments unless otherwise noted. The animal room was 
maintained at a constant temperature of 22.0 ± 0.6°C by the 
air conditioner. A 12/12‑h light/dark cycle was maintained; 
with lights on at 0600 h. Experimental protocol of the 
study was approved by the Ethical Committee of University 
Medical Faculty of our tertiary center (2013‑31). Animals 
were maintained and used in accordance with the animal 
welfare act and guide for the care and use of laboratory 
animals. Rats were randomly divided into three groups as 
follows:
•  Group 1 (traumatic extraction group) (n = 10)
•  Group 2 (atraumatic extraction group) (n = 10)and
•  Group 3 (no extraction, control group) (n = 10).
An experimental model of BRONJ was induced in all 30 rats 
by weekly subcutaneous (SC) doses of ZA (Zomebon, Koçak 
Farma, İstanbul, Turkey) (0.3 mg/kg/week)[1] for 60 days. 
The drug was dissolved in sterile physiological saline (0.9% 
NaCl) and diluted to the given concentration.
Surgical procedure
After 60 days of the pharmacologic therapy, Group 1 
was subjected to traumatic extractions, and Group 2 was 
subjected to atraumatic extractions of the right first lower 
molars (M1) by the same professional. Group 3 were 
subjected to no extractions. Teeth extraction was performed 
under general anesthesia by a combination of ketamine 
chloridrate (Ketalar; Eczacibasi, Turkey 0.08 mL/100 g 
body weight) and xylazine 2% (Rompun; Bayer, Germany; 
0.04 mL/100 g body weight).
For dental extraction the rats of Group 1 (traumatic group) 
were placed in a dorsal position and fixed in a special device. 
The surrounding gingivae were carefully detached from 
the lower first molars with a dental explorer. Then, with a 
Hollenback Carver, the tooth was luxated and separated 
into two segments (mesial and distal) that were removed 
with a forceps adapted around the cervical line of the 
segments. In addition, the interdental septum was removed 
in this group. The gingivae were not sutured after tooth 
extraction. In Group 2 (atraumatic group), initially the rats 
were placed in a dorsal position and fixed in a special device. 
The surrounding gingivae were carefully detached from 
the lower first molars with a dental explorer. Then, with a 
Hollenback Carver, the tooth was luxated and separated into 
two segments (mesial and distal) that were removed with 
a forceps adapted around the cervical line of the segments. 
Irregular bone edges were shaved. Gingivae were sutured 
after tooth extraction. The rats of Group 3 (control group) 
were not submitted to tooth extraction.
After the surgical procedure, all animals received an 
intramuscular dose of ceftriaxon, 25 mg/kg (Rocephin®, 
Roche, Turkey) and carprofen, 4 mg/kg (Rimadyl®, 
Pfizer, Turkey). The ZA administration protocol was 
maintained until the animals’ death and animals were 
euthanized by cardiac puncture under anesthesia 32 days 
after tooth extractions.
Study data collected
Blood samples were collected on the time of sacrifice by 
cardiac puncture and centrifuged for plasma separation. 
For biochemical examination serum were frozen at −20°C 
until the measurement. Serum CTX‑1 level was analyzed 
according to manufacturer’s instructions by using CTX‑1 
ELISA kit (Hangzhou Eastbiopharm Co., Ltd., China). Serum 
concentrations of CTX‑1 were expressed in a unit of ng/mL.
Groups 1 and 2 rats were observed intraorally and findings 
were recorded after sacrifice procedure. Observed clinical 
findings were graded as follows: 
•  Grade 0 = complete mucosal healing
•  Grade 1 = unhealed mucosa and bone trabeculae
•  Grade 2 = bone sequestrum and pus.
At the end of all procedures, cephalometric X‑ray of Group 1 
and Group 2 rats was assessed for osteomyelitis. Radiological 
findings were graded as follows:
•  Grade 0 = radiolucent view smaller than tooth 
extraction socket
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•  Grade 1 = radiolucent view same as tooth extraction 
socket
•  Grade 2 = radiolucent view larger than tooth extraction 
socket.
All observations and scorings were performed by the same 
researcher.
Statistical analysis
The statistical calculations were carried out with the 
SPSS 18 software (SPSS 18 for Windows, SPSS Inc., 
Chicago, IL, USA). Clinical observations and radiological 
evaluation were compared among groups using Chi‑square 
test. Mann‑Whitney U‑tests for paired comparison were 
used to estimate the differences CTX values in among of 
the groups. Statistical significance level was accepted at 
P < 0.05.
Results
None of the rats died from all groups during the course of 
the experiment. All rats of all groups were not occurred 
unwanted condition until the end of the experiment, and 
none of the rats were excluded from the study. In general, 
animals tolerated the procedure well and demonstrated 
good hemostasis and rapid recovery from anesthesia. Gross 
evidence of the extraction site healing was seen in the 
majority of Group 2 animals. In contrast, in Group 1 open 
wounds and exposed bone were noted in rats.
Bone turnover marker
The bone resorption marker CTX‑1 showed a significant 
difference among groups (P = 0.0001). In comparison 
to the control group (Group 3) (3.19 ± 0.27), CTX‑1 
increased in Group 1 (3.77 ± 0.34; P = 0.0001) and Group 
2 (4.15 ± 0.34; P = 0.001) [Table 1 and Figure 1]. However, 
CTX‑1 was significantly higher in Group 2 than Group 1 
[Table 1 and Figure 1].
Clinical and radiological assessment
No, statistically significant changes were found for clinical and 
radiologic findings between Group 1 and Group 2 (P ˃ 0.05) 
[Table 2]. As for the clinical evaluation, complete mucosal 
healing was observed in 80% of the rats in atraumatic extraction 
group while observed in 30% of the rats in traumatic extraction 
group. Conversely, bone sequestrum and pus were observed in 
10% of the rats in atraumatic group, whereas observed in 40% 
of the rats in traumatic group [Figure 2]. As for the radiological 
evaluation, radiolucent view smaller than tooth extraction 
socket was observed in 70% of the rats in atraumatic extraction 
group, while observed in 40% of the rats in traumatic extraction 
group. Conversely, radiolucent view larger than tooth extraction 
socket was observed in 10% of the rats in atraumatic group, 
while observed in 30% of the rats in traumatic group [Figure 3].
Discussion
In this study, we aimed to mimic the clinical presentation of 
BRONJ in a rat animal model since successful recapitulation 











CTX 3.77±0.34 4.15±0.34 3.19±0.27 0.0001 P (Group 1 vs. Group 2)=0.021
P (Group 2 vs. Group 3)=0.001
P (Group 1 vs. Group 3)=0.0001
CTX=C-terminal telopeptide
Figure 1: Comparison of C-terminal cross-linking telopeptide of 
type I collagen values among groups
Figure 2: Bone sequestrum and pus due to necrosis in the teeth 
extraction area
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of a BRONJ‑like indication in a rodent model will be 
useful for studying pathogenesis, as well as preventative 
and treatment strategies for BRONJ. Compatible with the 
literature, we have determined that in traumatic group of 
rats receiving ZA, CTX‑1 levels were higher than that of 
atraumatic rats and control group cases. However, although 
the clinical and radiological data were better on atraumatic 
group, the difference between traumatic and atraumatic 
cases was not statistically significant.
As can be seen with the increasing number of reports 
on BRONJ from the scientific community, many efforts 
have been made to obtain experimental models of these 
lesions.[10,11] Several hypotheses concerning the pathogenesis 
of BRONJ have been proposed, but none has been accepted 
completely. However, analysis of data retrieved from clinical 
studies suggests that some cofactors may play a relevant role 
in the development of these lesions, even in the presence 
of BRONJ with no obvious comorbidity factors.[12] The 
models of osteonecrosis of the jaw (ONJ)‑like lesions 
have been published in the literature, being developed by 
the association of BP therapy, tooth extraction and other 
cofactors, such as concomitant steroid use, vitamin D 
deficiency or increased socket damage.[11,13,14]
Although BRONJ can occur spontaneously, most of the 
reports have been associated with surgical procedures.[15,16] 
In this study, we opted to use tooth extraction as a trigger, 
based on the fact that analysis of data retrieved from clinical 
and in vivo studies suggested a strong relationship between 
tooth extraction and BRONJ.[17,18] The clinical diagnosis 
of BRONJ is defined as an area of exposed bone in the 
maxillofacial region which did not heal within 8 weeks in 
a patient who is or was exposed to a BP and did not have 
radiation therapy to the craniofacial region.[19] Although 
the alveolar healing phases are similar in both humans and 
rats, they occur more rapidly in rodents than in humans, 
lasting about one‑third of the time required for human 
healing.[20,21] Therefore, the 4 weeks bone exposure in 
rats observed in this study could be considered a clinical 
equivalent concept of ONJ induced by BP in rats. To 
support this assumption, studies have shown transient 
impairment of BPs in alveolar socket healing, and these 
effects have not been extended beyond 14 days.[22] When 
the rats were investigated in this regard it has been 
determined that rats with Grades 1 and 2 clinical picture 
can be diagnosed with BRONJ and the ratios of rats with 
BRONJ in traumatic and atraumatic groups respectively 
were 70% and 20%. Although there was not a statistically 
significant difference in regards to the clinical and 
radiological findings of these two groups, when the groups 
were evaluated for the presence of  BRONJ clinically, 
the difference was statistically significant (P = 0.0001). 
Similarly, Marx had reported that in 110 (72.3%) of 152 
BRONJ cases history tooth extraction was present with 
periodontal inflammation.[23]
Zoledronic acid has a strong affinity to bone mineral and 
exerts antiresorptive effects by targeting osteoclasts.[24] 
Since osteoclasts play an important role in hematopoiesis, 
chronically suppressed osteoclasts would likely alter 
cellular responses during wound healing.[25] This could 
be in connection with the development of the BRONJ. 
In this study, high dose of ZA was administered for an 
extended duration; both the dose and duration of the drug 
are considered as known risk factors for BRONJ. However, 
with this high doses and long duration of ZA treatment, in 
atraumatic rats BRONJ was investigated in 20% of cases 
demonstrating that ZA treatment is not the only factor 
determining BRONJ development. In literature, the risk 
of BRONJ development for patients on intravenous BPs is 
estimated at between 1% and 11%, which increases after 
longer treatment time and in patients on ZA.[26,27] The 
higher ratios of BRONJ cases in atraumatic group in our 
study may be associated with longer treatment durations 
and/or ZA.
Bisphosphonates  have been administered  by 
non‑intravenous (IV) route in many other rodent studies.[28] 
While the drug is usually administered IV in humans, we 
administered the drug SC in rats. In our experiments, we 
use SC injections, which could mean that less BP is entering 
the systemic circulation. With higher doses or intravenous 
administration, this could hypothetically constitute a 
negative influence on bone formation. Further, a prolonged 
Table 2: Comparison of atraumatic and traumatic 
groups for clinical and radiological evaluation
Evaulation 
Parameters








Grade 0 8 (80) 3 (30) 0.079
Grade 1 1 (10) 3 (30)
Grade 2 1 (10) 4 (40)
Total 10 (100) 10 (100)
Radiological evaluation
Grade 0 7 (70) 4 (40) 0.365
Grade 1 2 (20) 3 (30)
Grade 2 1 (10) 3 (30)
Total 10 (100) 10 (100)
Figure 3: Cephalometric X-ray showing no lesion in the control 
group (a), and necrosis on the teeth extraction area (b)
ba
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effect of the drug with slow‑release effects could be the 
effect of a SC deposition compared to an intravenous 
administration.
Serum CTX values have been used as biochemical markers 
of bone formation and resorption. The first clinical 
application of CTX measurement for predicting BRONJ 
was reported by Marx et al.[29] Conversely, Kunchur et al. 
concluded that CTX is not predictive of the development 
of BRONJ.[9] Biochemical markers of bone turnover provide 
insight into the dynamic changes of the skeleton and are 
primarily used as research tools to study the pathogenesis 
and treatment of bone diseases.[30] Research using bone 
biomarkers has suggested their clinical use to monitor 
the effect of antiresorptive therapy, predict bone loss and 
fracture in osteoporosis, predict complications of metastatic 
bone disease, and to identify the progression of joint damage 
in rheumatoid arthritis and the extent of bone involvement 
in metastatic cancer and multiple myeloma.[31,32] Bone 
biomarkers have been reported to be especially relevant 
in patients who have a history of oral BP use. Because of 
differences in bony metabolism and aging rates between 
rats and humans, even a short exposure to ZA was 
sufficient to elicit changes in serum CTX level compared 
to untreated controls. Thus, in an attempt to increase the 
model’s reliability, we reduced the number of variables and 
demonstrated the development of experimental BRONJ‑like 
lesions using the combination of BPs therapy and different 
tooth extraction methods (traumatic or atraumatic) in this 
study.
The main limitation of this study was that we did not 
examine the necrosis of mandible histopathologically in 
the diagnosis of BRONJ. However, BRONJ was diagnosed 
clinically according to its previous definitions. On the other 
hand, although the clinical and radiological findings of 
the atraumatic group were better, the difference between 
traumatic and atraumatic groups was not statistically 
significant, which in turn may be the result of the low 
number of rats included in the study. Larger studies may 
give more precise data about this topic.
Conclusion
This study provides preliminary observations for the 
development of an animal model of BRONJ. Although 
clinical and radiological findings were not relevant, 
CTX‑1 values and the prevalence of clinically diagnosed 
BRONJ cases significantly differed in extraction groups 
with or without trauma. The results also suggest that 
traumatic extractions with periodontal changes may 
predispose patients to higher CTX levels and also BRONJ. 
We concluded that tooth extraction with trauma effects 
on levels of serum CTX, which may be a marker for 
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